Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Diffusion basis spectrum imaging for identifying pathologies in MS subtypes.

Shirani A, Sun P, Trinkaus K, Perantie DC, George A, Naismith RT, Schmidt RE, Song SK, Cross AH.

Ann Clin Transl Neurol. 2019 Oct 6. doi: 10.1002/acn3.50903. [Epub ahead of print]

2.

Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS).

Matza LS, Stewart KD, Phillips G, Delio P, Naismith RT.

Mult Scler Relat Disord. 2019 Jun 19;35:253-261. doi: 10.1016/j.msard.2019.06.024. [Epub ahead of print]

PMID:
31437740
3.

Use of gadolinium for MRI diagnostic or surveillance studies in patients with MS.

Haider L, Naismith RT, Rovira A.

Neurology. 2019 Aug 6;93(6):239-240. doi: 10.1212/WNL.0000000000007891. Epub 2019 Jul 8. No abstract available.

PMID:
31285397
4.

Incorporating non-linear alignment and multi-compartmental modeling for improved human optic nerve diffusion imaging.

Kim JW, Andersson JL, Seifert AC, Sun P, Song SK, Dula C, Naismith RT, Xu J.

Neuroimage. 2019 Aug 1;196:102-113. doi: 10.1016/j.neuroimage.2019.03.058. Epub 2019 Mar 28.

PMID:
30930313
5.

The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: a brief report.

Shirani A, Cross AH, Naismith RT; Multiple Sclerosis Partners Advancing Technology and Health Solutions Investigators#.

Mult Scler J Exp Transl Clin. 2019 Feb 26;5(1):2055217319832031. doi: 10.1177/2055217319832031. eCollection 2019 Jan-Mar.

6.

Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.

Naismith RT, Hendin B, Wray S, Huang D, Gaudenzi F, Dong Q, Sperling B, Mann M, Werneburg B.

Mult Scler J Exp Transl Clin. 2019 Jan 30;5(1):2055217318822148. doi: 10.1177/2055217318822148. eCollection 2019 Jan-Mar.

7.

Optical coherence tomography for diagnosing optic neuritis: Are we there yet?

Saidha S, Naismith RT.

Neurology. 2019 Feb 5;92(6):253-254. doi: 10.1212/WNL.0000000000006866. Epub 2019 Jan 23. No abstract available.

PMID:
30674597
8.

Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.

Solomon AJ, Naismith RT, Cross AH.

Neurology. 2019 Jan 1;92(1):26-33. doi: 10.1212/WNL.0000000000006583. Epub 2018 Oct 31. Review.

PMID:
30381369
9.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
10.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

11.

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.

Hendin B, Naismith RT, Wray SE, Huang D, Dong Q, Livingston T, Jones DL, Watson C, Jhaveri M.

Patient Prefer Adherence. 2018 Jul 20;12:1289-1297. doi: 10.2147/PPA.S157317. eCollection 2018.

12.

Histopathological correlation of diffusion basis spectrum imaging metrics of a biopsy-proven inflammatory demyelinating brain lesion: A brief report.

Shirani A, Sun P, Schmidt RE, Trinkaus K, Naismith RT, Song SK, Cross AH.

Mult Scler. 2018 Jul 1:1352458518786072. doi: 10.1177/1352458518786072. [Epub ahead of print]

PMID:
29992856
13.

Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis.

Adusumilli G, Lancia S, Levasseur VA, Amblee V, Orchard M, Wagner JM, Naismith RT.

PLoS One. 2018 Jun 7;13(6):e0198178. doi: 10.1371/journal.pone.0198178. eCollection 2018.

14.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
15.

Refining the use of MRI to predict multiple sclerosis.

Cross AH, Naismith RT.

Lancet Neurol. 2018 Feb;17(2):105-106. doi: 10.1016/S1474-4422(17)30459-3. Epub 2017 Dec 21. No abstract available.

PMID:
29275978
16.

Intensity ratio to improve black hole assessment in multiple sclerosis.

Adusumilli G, Trinkaus K, Sun P, Lancia S, Viox JD, Wen J, Naismith RT, Cross AH.

Mult Scler Relat Disord. 2018 Jan;19:140-147. doi: 10.1016/j.msard.2017.11.020. Epub 2017 Dec 2.

17.

OCT as a window to the MS brain: The view becomes slightly clearer.

Toosy AT, Naismith RT, Villoslada P.

Neurology. 2017 Dec 12;89(24):2404-2405. doi: 10.1212/WNL.0000000000004755. Epub 2017 Nov 15. No abstract available.

PMID:
29142085
18.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Review.

19.

Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.

Baldassari LE, Salter AR, Longbrake EE, Cross AH, Naismith RT.

Mult Scler. 2018 Sep;24(10):1347-1355. doi: 10.1177/1352458517721357. Epub 2017 Aug 2.

PMID:
28766993
20.

Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.

Clerico M, De Mercanti S, Artusi CA, Durelli L, Naismith RT.

Mult Scler. 2017 May;23(6):874-876. doi: 10.1177/1352458516688350. Epub 2017 Feb 1.

PMID:
28290755
21.

Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study.

Hendin B, Huang D, Wray S, Naismith RT, Rosenblatt S, Zambrano J, Werneburg B.

Neurodegener Dis Manag. 2017 Feb;7(1):39-47. doi: 10.2217/nmt-2016-0032. Epub 2017 Jan 10.

22.

Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis.

Longbrake EE, Lancia S, Tutlam N, Trinkaus K, Naismith RT.

Mult Scler Relat Disord. 2016 Nov;10:198-203. doi: 10.1016/j.msard.2016.10.009. Epub 2016 Nov 4.

23.

High-Frequency Learning Goals: Using Self-Regulated Learning to Influence Day-to-Day Practice in Clinical Education.

Larsen DP, Naismith RT, Margolis M.

Teach Learn Med. 2017 Jan-Mar;29(1):93-100. doi: 10.1080/10401334.2016.1230501. Epub 2016 Nov 4.

PMID:
27813672
24.

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.

Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG.

Neurology. 2016 Sep 27;87(13):1393-9. doi: 10.1212/WNL.0000000000003152. Epub 2016 Aug 31.

25.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

26.

Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO.

Naismith RT.

Mult Scler. 2016 Oct;22(11):1400-1402. Epub 2016 Jun 8. No abstract available.

PMID:
27279590
27.

Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures.

Alvarez E, Piccio L, Mikesell RJ, Trinkaus K, Parks BJ, Naismith RT, Cross AH.

Mult Scler J Exp Transl Clin. 2015 Dec 24;1:2055217315623800. doi: 10.1177/2055217315623800. eCollection 2015 Jan-Dec.

28.

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance.

Longbrake EE, Naismith RT, Parks BJ, Wu GF, Cross AH.

Mult Scler J Exp Transl Clin. 2015 Jan-Dec;1. pii: 2055217315596994. Epub 2015 Jul 31.

29.

Enhancing our understanding of white matter changes in early multiple sclerosis.

Naismith RT, Cross AH.

Brain. 2015 Sep;138(Pt 9):2465-6. doi: 10.1093/brain/awv196. No abstract available.

PMID:
26304148
30.

Cortical Lesions in Multiple Sclerosis: Clinical Relevance for a Hidden Disease Burden.

Naismith RT.

JAMA Neurol. 2015 Sep;72(9):979-80. doi: 10.1001/jamaneurol.2015.1422. No abstract available.

PMID:
26191784
31.

Using MRI to make informed clinical decisions in multiple sclerosis care.

Bermel RA, Naismith RT.

Curr Opin Neurol. 2015 Jun;28(3):244-9. doi: 10.1097/WCO.0000000000000204. Review.

PMID:
25887772
32.

Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.

Wang Y, Sun P, Wang Q, Trinkaus K, Schmidt RE, Naismith RT, Cross AH, Song SK.

Brain. 2015 May;138(Pt 5):1223-38. doi: 10.1093/brain/awv046. Epub 2015 Feb 26.

33.

Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.

Goldman MD, Naismith RT.

Neurology. 2015 Mar 3;84(9):864-5. doi: 10.1212/WNL.0000000000001319. Epub 2015 Jan 30. No abstract available.

PMID:
25636716
34.

Examining multiple sclerosis through the eyes of a child.

Naismith RT, Narayanan D.

Neurology. 2014 Dec 2;83(23):2108-9. doi: 10.1212/WNL.0000000000001060. Epub 2014 Oct 31. No abstract available.

PMID:
25361782
35.

Antisense therapy: potential tool to reduce activity in MS via protein expression inhibition.

Naismith RT, Cross AH.

Neurology. 2014 Nov 11;83(20):1776-7. doi: 10.1212/WNL.0000000000000927. Epub 2014 Sep 19. No abstract available.

PMID:
25239837
36.

Natalizumab to fingolimod washout in patients at risk of PML: when good intentions yield bad outcomes.

Giovannoni G, Naismith RT.

Neurology. 2014 Apr 8;82(14):1196-7. doi: 10.1212/WNL.0000000000000296. Epub 2014 Mar 7.

PMID:
24610331
37.

Plantarflexor weakness negatively impacts walking in persons with multiple sclerosis more than plantarflexor spasticity.

Wagner JM, Kremer TR, Van Dillen LR, Naismith RT.

Arch Phys Med Rehabil. 2014 Jul;95(7):1358-65. doi: 10.1016/j.apmr.2014.01.030. Epub 2014 Feb 28.

38.

Established and novel disease-modifying treatments in multiple sclerosis.

Cross AH, Naismith RT.

J Intern Med. 2014 Apr;275(4):350-63. doi: 10.1111/joim.12203. Epub 2014 Mar 11. Review.

39.

BCG vaccine for clinically isolated syndrome and MS: infections and protective immunity.

Bourdette D, Naismith RT.

Neurology. 2014 Jan 7;82(1):15-6. doi: 10.1212/01.wnl.0000438232.40847.c3. Epub 2013 Dec 4. No abstract available.

PMID:
24306000
40.

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.

Fenoglio C, Ridolfi E, Cantoni C, De Riz M, Bonsi R, Serpente M, Villa C, Pietroboni AM, Naismith RT, Alvarez E, Parks BJ, Bresolin N, Cross AH, Piccio LM, Galimberti D, Scarpini E.

Mult Scler. 2013 Dec;19(14):1938-42. doi: 10.1177/1352458513485654.

PMID:
24277735
41.

Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease.

Naismith RT, Xu J, Klawiter EC, Lancia S, Tutlam NT, Wagner JM, Qian P, Trinkaus K, Song SK, Cross AH.

Neurology. 2013 Jun 11;80(24):2201-9. doi: 10.1212/WNL.0b013e318296e8f1. Epub 2013 May 10.

42.

Four Square Step Test in ambulant persons with multiple sclerosis: validity, reliability, and responsiveness.

Wagner JM, Norris RA, Van Dillen LR, Thomas FP, Naismith RT.

Int J Rehabil Res. 2013 Sep;36(3):253-9. doi: 10.1097/MRR.0b013e32835fd97f.

PMID:
23511117
43.

Can "dissemination" include the PNS in adults with acute disseminated encephalomyelitis?

Naismith RT, Banwell BL.

Neurology. 2013 Mar 5;80(10):876-7. doi: 10.1212/WNL.0b013e3182840cea. Epub 2013 Jan 16. No abstract available.

PMID:
23325898
44.

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.

Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT, Cross AH.

Mult Scler. 2013 Aug;19(9):1204-8. doi: 10.1177/1352458512473362. Epub 2013 Jan 15.

45.

Improved in vivo diffusion tensor imaging of human cervical spinal cord.

Xu J, Shimony JS, Klawiter EC, Snyder AZ, Trinkaus K, Naismith RT, Benzinger TL, Cross AH, Song SK.

Neuroimage. 2013 Feb 15;67:64-76. doi: 10.1016/j.neuroimage.2012.11.014. Epub 2012 Nov 21.

46.

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J, Harris C, Herbert J, Li D, Lincoln JA, Lisak R, Lublin FD, Lucchinetti CF, Moore W, Naismith RT, Oehninger C, Simon J, Sormani MP.

Int J MS Care. 2012 Fall;14(3):105-14. doi: 10.7224/1537-2073-14.3.105.

47.

Association of neuromyelitis optica with severe and intractable pain.

Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT.

Arch Neurol. 2012 Nov;69(11):1482-7.

48.

Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis.

Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, Van Stavern GP.

J Neuroophthalmol. 2012 Sep;32(3):216-20. doi: 10.1097/WNO.0b013e318254c62d.

PMID:
22659839
49.

Increased radial diffusivity in spinal cord lesions in neuromyelitis optica compared with multiple sclerosis.

Klawiter EC, Xu J, Naismith RT, Benzinger TL, Shimony JS, Lancia S, Snyder AZ, Trinkaus K, Song SK, Cross AH.

Mult Scler. 2012 Sep;18(9):1259-68. doi: 10.1177/1352458512436593. Epub 2012 Feb 21.

50.

Supplemental Content

Loading ...
Support Center